title: Therapeutic options for HER-2 positive breast cancer: Perspectives and future directions.
abstract: During the last 15 years we have witnessed an unprecedented expansion in the drugs developed to target human epidermal growth factor receptor-2 (HER-2) positive breast cancer. Trastuzumab, pertuzumab, ado-trastuzumab emtansine and lapatinib are currently food and drug administration (FDA)-approved for the treatment of breast cancer patients with HER-2 over-expressed. However, given the amount of information gathered from years of uninterrupted clinical research, it is essential to have periodic updates that succinctly recapitulate what we have learnt over these last years and help us to apply that information in our daily practice. This review will pursue that objective. We will summarize the most relevant and updated information related to the state of the art management of HER-2 positive breast cancer in all the clinical scenarios including the adjuvant, neoadjuvant and metastatic settings. But we will also critically appraise that literature in order to highlight some key clinical concepts that should not be overlooked. Lastly, this review will also point out some of the most promising strategies that are currently being tested and may soon become available.
authors.affiliation: Gonzalo Recondo Jr, Enrique Dìaz Canton, Màximo de la Vega, Martin Greco, Gonzalo Recondo Sr, Centro de Educación Médica e Investigaciones Clínicas (CEMIC), 4102 Buenos Aires, Argentina.
authors.forename: Gonzalo
authors.initials: G
authors.lastname: Recondo
authors.affiliation: Gonzalo Recondo Jr, Enrique Dìaz Canton, Màximo de la Vega, Martin Greco, Gonzalo Recondo Sr, Centro de Educación Médica e Investigaciones Clínicas (CEMIC), 4102 Buenos Aires, Argentina.
authors.forename: Enrique
authors.initials: E
authors.lastname: Dìaz Canton
authors.affiliation: Gonzalo Recondo Jr, Enrique Dìaz Canton, Màximo de la Vega, Martin Greco, Gonzalo Recondo Sr, Centro de Educación Médica e Investigaciones Clínicas (CEMIC), 4102 Buenos Aires, Argentina.
authors.forename: Màximo
authors.initials: M
authors.lastname: de la Vega
authors.affiliation: Gonzalo Recondo Jr, Enrique Dìaz Canton, Màximo de la Vega, Martin Greco, Gonzalo Recondo Sr, Centro de Educación Médica e Investigaciones Clínicas (CEMIC), 4102 Buenos Aires, Argentina.
authors.forename: Martin
authors.initials: M
authors.lastname: Greco
authors.affiliation: Gonzalo Recondo Jr, Enrique Dìaz Canton, Màximo de la Vega, Martin Greco, Gonzalo Recondo Sr, Centro de Educación Médica e Investigaciones Clínicas (CEMIC), 4102 Buenos Aires, Argentina.
authors.forename: Gonzalo
authors.initials: G
authors.lastname: Recondo
authors.affiliation: Gonzalo Recondo Jr, Enrique Dìaz Canton, Màximo de la Vega, Martin Greco, Gonzalo Recondo Sr, Centro de Educación Médica e Investigaciones Clínicas (CEMIC), 4102 Buenos Aires, Argentina.
authors.forename: Matias E
authors.initials: ME
authors.lastname: Valsecchi
keywords: Ado-trastuzumab; Breast cancer; Human epidermal growth factor receptor-2; Lapatinib; Pertuzumab; Trastuzumab
references.citation: CA Cancer J Clin. 2011 Mar-Apr;61(2):69-90
references.pmid: 21296855
references.citation: Lancet Oncol. 2013 May;14(6):461-71
references.pmid: 23602601
references.citation: Oncologist. 2004;9 Suppl 3:10-5
references.pmid: 15163842
references.citation: N Engl J Med. 2012 Nov 8;367(19):1783-91
references.pmid: 23020162
references.citation: J Clin Oncol. 2012 Sep 10;30(26):3234-41
references.pmid: 22649126
references.citation: J Steroid Biochem. 1989;34(1-6):123-31
references.pmid: 2576295
references.citation: Eur J Cancer. 2011 Oct;47(15):2273-81
references.pmid: 21741829
references.citation: J Clin Oncol. 2010 Mar 1;28(7):1138-44
references.pmid: 20124182
references.citation: Cancer Res. 2005 Dec 1;65(23):11118-28
references.pmid: 16322262
references.citation: Lancet Oncol. 2013 Jan;14(1):88-96
references.pmid: 23234763
references.citation: Br J Cancer. 2011 Jun 7;104(12):1828-35
references.pmid: 21559012
references.citation: Cancer. 2007 Sep 1;110(5):965-72
references.pmid: 17614302
references.citation: Lancet Oncol. 2012 Feb;13(2):135-44
references.pmid: 22257523
references.citation: Ann Oncol. 2009 Jun;20(6):1026-31
references.pmid: 19179558
references.citation: J Clin Oncol. 2012 Jul 20;30(21):2585-92
references.pmid: 22689807
references.citation: Cancer Manag Res. 2010 Jan 07;2:13-25
references.pmid: 21188093
references.citation: J Clin Oncol. 2005 Jun 1;23(16):3676-85
references.pmid: 15738535
references.citation: J Clin Oncol. 2009 Apr 20;27(12):1999-2006
references.pmid: 19289619
references.citation: J Clin Oncol. 2010 Mar 1;28(7):1124-30
references.pmid: 20124187
references.citation: Breast Cancer Res Treat. 2012 Jun;133(3):1057-65
references.pmid: 22418700
references.citation: Clin Cancer Res. 2011 Aug 1;17(15):5132-9
references.pmid: 21558407
references.citation: Lancet Oncol. 2012 Sep;13(9):869-78
references.pmid: 22884505
references.citation: J Clin Oncol. 2011 Dec 1;29(34):4491-7
references.pmid: 22042958
references.citation: J Clin Oncol. 2013 Mar 20;31(9):1157-63
references.pmid: 23382472
references.citation: J Clin Oncol. 2010 Dec 1;28(34):5110-5
references.pmid: 20975068
references.citation: Clin Cancer Res. 2000 Apr;6(4):1347-50
references.pmid: 10778962
references.citation: J Clin Oncol. 2012 May 20;30(15):1796-804
references.pmid: 22508812
references.citation: Nat Rev Mol Cell Biol. 2001 Feb;2(2):127-37
references.pmid: 11252954
references.citation: Cancer Cell. 2007 Oct;12(4):395-402
references.pmid: 17936563
references.citation: J Clin Oncol. 2009 Oct 1;27(28):4685-92
references.pmid: 19720923
references.citation: Tumori. 2004 Jan-Feb;90(1):40-3
references.pmid: 15143970
references.citation: Curr Med Res Opin. 2013 Apr;29(4):405-14
references.pmid: 23402224
references.citation: EMBO Rep. 2004 Dec;5(12):1165-70
references.pmid: 15568014
references.citation: Ann Oncol. 2013 Jan;24(1):109-16
references.pmid: 22967996
references.citation: J Clin Oncol. 2009 Dec 20;27(36):6129-34
references.pmid: 19917839
references.citation: Ann Oncol. 2013 Jun;24(6):1526-33
references.pmid: 23463626
references.citation: Ann Oncol. 2013 Sep;24(9):2278-84
references.pmid: 23704196
references.citation: Lancet. 2013 Sep 21;382(9897):1021-8
references.pmid: 23871490
references.citation: J Clin Oncol. 2005 Apr 10;23(11):2534-43
references.pmid: 15699478
references.citation: Lancet Oncol. 2013 Nov;14(12):1183-92
references.pmid: 24095300
references.citation: J Clin Oncol. 2009 Nov 20;27(33):5529-37
references.pmid: 19786670
references.citation: Cell. 1994 Jul 15;78(1):5-8
references.pmid: 8033211
references.citation: J Clin Oncol. 2009 Dec 1;27(34):5685-92
references.pmid: 19884557
references.citation: Cochrane Database Syst Rev. 2007 Apr 18;(2):CD005002
references.pmid: 17443564
references.citation: J Clin Oncol. 2010 Mar 10;28(8):1301-7
references.pmid: 20142587
references.citation: Adv Cancer Res. 1998;74:49-139
references.pmid: 9561267
references.citation: J Clin Oncol. 2002 Feb 1;20(3):719-26
references.pmid: 11821453
references.citation: J Clin Oncol. 2011 Sep 1;29(25):3351-7
references.pmid: 21788566
references.citation: J Clin Oncol. 2007 Dec 1;25(34):5410-7
references.pmid: 18048823
references.citation: N Engl J Med. 2010 Nov 11;363(20):1938-48
references.pmid: 21067385
references.citation: Cancer Res. 2004 Jun 1;64(11):3958-65
references.pmid: 15173008
references.citation: Lancet Oncol. 2012 Jan;13(1):25-32
references.pmid: 22153890
references.citation: Nat Med. 2011 Apr;17(4):461-9
references.pmid: 21399647
references.citation: Lancet Oncol. 2013 Jul;14(8):741-8
references.pmid: 23764181
references.citation: N Engl J Med. 2006 Feb 23;354(8):809-20
references.pmid: 16495393
references.citation: Lancet Oncol. 2013 Jan;14(1):64-71
references.pmid: 23122784
references.citation: Oncologist. 2013;18(11):1153-66
references.pmid: 24212500
references.citation: Clin Cancer Res. 2007 Jan 1;13(1):228-33
references.pmid: 17200359
references.citation: N Engl J Med. 2012 Jan 12;366(2):109-19
references.pmid: 22149875
references.citation: Proc Natl Acad Sci U S A. 2011 Mar 22;108(12):5021-6
references.pmid: 21385943
references.citation: J Oncol. 2013;2013:854121
references.pmid: 23737784
references.citation: Breast Cancer Res Treat. 2008 Dec;112(3):533-43
references.pmid: 18188694
references.citation: J Clin Oncol. 2010 Mar 1;28(7):1131-7
references.pmid: 20124183
references.citation: N Engl J Med. 2006 Dec 28;355(26):2733-43
references.pmid: 17192538
references.citation: Lancet Oncol. 2013 Dec;14(13):1317-25
references.pmid: 24239210
references.citation: J Transl Med. 2012 Feb 10;10:28
references.pmid: 22325452
references.citation: Lancet. 2010 Jan 30;375(9712):377-84
references.pmid: 20113825
references.citation: Lancet. 2012 Feb 18;379(9816):633-40
references.pmid: 22257673
references.citation: J Natl Cancer Inst. 2003 Jan 15;95(2):142-53
references.pmid: 12529347
references.citation: N Engl J Med. 2005 Oct 20;353(16):1659-72
references.pmid: 16236737
references.citation: N Engl J Med. 2001 Mar 15;344(11):783-92
references.pmid: 11248153
references.citation: N Engl J Med. 2012 Jun 28;366(26):2438-41
references.pmid: 22646508
references.citation: Clin Cancer Res. 2002 May;8(5):1014-8
references.pmid: 12006513
references.citation: J Clin Oncol. 2011 Sep 1;29(25):3366-73
references.pmid: 21768458
references.citation: J Pharmacol Exp Ther. 2012 Nov;343(2):342-50
references.pmid: 22888144
references.citation: J Clin Oncol. 2009 Nov 20;27(33):5538-46
references.pmid: 19786658
references.citation: J Clin Oncol. 2010 Apr 20;28(12):2024-31
references.pmid: 20308670
references.citation: N Engl J Med. 2005 Oct 20;353(16):1673-84
references.pmid: 16236738
references.citation: J Clin Oncol. 2007 Aug 20;25(24):3680-7
references.pmid: 17704416
references.citation: N Engl J Med. 2011 Oct 6;365(14):1273-83
references.pmid: 21991949
references.citation: Clin Cancer Res. 2012 Sep 15;18(18):5110-22
references.pmid: 22811582
references.citation: Mol Cell Biol. 1999 Oct;19(10):6845-57
references.pmid: 10490623
references.citation: Breast. 2012 Feb;21(1):27-33
references.pmid: 21862331
references.citation: J Clin Oncol. 1999 Sep;17(9):2639-48
references.pmid: 10561337
references.citation: Bioessays. 1998 Jan;20(1):41-8
references.pmid: 9504046
references.citation: J Clin Oncol. 2006 Jun 20;24(18):2786-92
references.pmid: 16782917
references.citation: J Clin Oncol. 2002 Jun 1;20(11):2624-32
references.pmid: 12039923